<p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 免费报告）- HC Wainwright 的股票研究人员在 8 月 5 日星期二发布的研究报告中下调了对 Praxis Precision Medicines 2029 财年的每股收益预期。HC Wainwright 分析师 D. Tsao 现在预计该公司将公布每股收益为 21.43 美元，低于之前的 22.65 美元预期。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 115.00 美元。市场普遍预计 Praxis Precision Medicines 当前全年的每股收益为（10.22 美元）。</p>
<p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近在 8 月 4 日星期一公布了季度财报。该公司报告季度每股收益为（3.31 美元），超出分析师普遍预期的（3.40 美元）0.09 美元。Praxis Precision Medicines 的股本回报率为负的 59.42%，净利润率为负的 2,137.48%。</p>
<p>其他分析师最近也发布了关于该公司的研究报告。Needham &amp; Company LLC 在 6 月 12 日星期四重申了 “买入” 评级，并对 Praxis Precision Medicines 的股票设定了 80.00 美元的目标价。Wedbush 将 Praxis Precision Medicines 的目标价从 26.00 美元上调至 28.00 美元，并在 5 月 5 日星期一的研究报告中给予该股票 “跑输大盘” 的评级。Chardan Capital 在 7 月 29 日星期二的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价。最后，Oppenheimer 在 7 月 8 日星期二将 Praxis Precision Medicines 的目标价从 97.00 美元上调至 115.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了 “卖出” 评级，八位分析师则给予了 “买入” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 95.22 美元。</p>
<p><strong>查看我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
<h2>Praxis Precision Medicines 股价下跌 6.5%</h2>
<p>PRAX 股票在星期三开盘价为 47.79 美元。该股票的 50 日移动平均线为 47.56 美元，200 日移动平均线为 48.66 美元。Praxis Precision Medicines 的 12 个月低点为 26.70 美元，12 个月高点为 91.83 美元。该公司的市值为 9.7348 亿美元，市盈率为 -3.89，贝塔系数为 2.62。</p>
<h2>对 Praxis Precision Medicines 的对冲基金看法</h2>
<p>几家机构投资者最近买入和卖出了该公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第四季度将其在 Praxis Precision Medicines 的持仓增加了 2.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 11,135 股该公司的股票，价值 856,000 美元，此前在上个季度购买了 258 股。加利福尼亚州教师退休系统在第四季度将其在 Praxis Precision Medicines 的持仓增加了 2.2%。加利福尼亚州教师退休系统目前拥有 12,726 股该公司的股票，价值 979,000 美元，此前在上个季度购买了 275 股。Nisa Investment Advisors LLC 在第二季度将其在 Praxis Precision Medicines 的持仓增加了 88.3%。Nisa Investment Advisors LLC 目前拥有 629 股该公司的股票，价值 26,000 美元，此前在上个季度购买了 295 股。GF Fund Management CO. LTD. 在第四季度购买了 Praxis Precision Medicines 的新头寸，价值 30,000 美元。最后，MetLife Investment Management LLC 在第四季度将其在 Praxis Precision Medicines 的持仓增加了 5.4%。MetLife Investment Management LLC 目前拥有 10,675 股该公司的股票，价值 822,000 美元，此前在上个季度购买了 544 股。机构投资者持有该公司 67.84% 的股份。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（获取免费报告）</p>
<p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗特发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票，超过 Praxis Precision Medicines</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>三只在财报超预期后火热的行业 ETF</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>不寻常的机器：一种有助于提升其价格的投机</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>Zebra Technologies：乘着自动化浪潮获利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
<p>在你考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRAX

<p>HC Wainwright 已将 Praxis Precision Medicines (NASDAQ:PRAX) 的 2029 财年每股收益预期从 $22.65 下调至 $21.43。该公司维持 “买入” 评级，目标价为 $115.00。市场对该公司当前全年的每股收益共识预期为 ($10.22)。Praxis 在上个季度报告的每股收益为 ($3.31)，超出预期。该股票在过去 12 个月的交易区间为 $26.70 至 $91.83，目前交易价格为 $47.79，下跌 6.5%。机构投资者持有 67.84% 的股份</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities researchers at HC Wainwright lowered their FY2029 earnings per share estimates for shares of Praxis Precision Medicines in a research report issued on Tuesday, August 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $21.43 for the year, down from their prior estimate of $22.65. HC Wainwright currently has a &#34;Buy&#34; rating and a $115.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 免费报告）- HC Wainwright 的股票研究人员在 8 月 5 日星期二发布的研究报告中下调了对 Praxis Precision Medicines 2029 财年的每股收益预期。HC Wainwright 分析师 D. Tsao 现在预计该公司将公布每股收益为 21.43 美元，低于之前的 22.65 美元预期。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 115.00 美元。市场普遍预计 Praxis Precision Medicines 当前全年的每股收益为（10.22 美元）。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($3.31) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 59.42% and a negative net margin of 2,137.48%.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近在 8 月 4 日星期一公布了季度财报。该公司报告季度每股收益为（3.31 美元），超出分析师普遍预期的（3.40 美元）0.09 美元。Praxis Precision Medicines 的股本回报率为负的 59.42%，净利润率为负的 2,137.48%。</p>
</div><p>Other analysts also recently issued research reports about the company. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. Wedbush raised their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an &#34;underperform&#34; rating in a research report on Monday, May 5th. Chardan Capital restated a &#34;buy&#34; rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. Finally, Oppenheimer raised their target price on Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $95.22.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该公司的研究报告。Needham &amp; Company LLC 在 6 月 12 日星期四重申了 “买入” 评级，并对 Praxis Precision Medicines 的股票设定了 80.00 美元的目标价。Wedbush 将 Praxis Precision Medicines 的目标价从 26.00 美元上调至 28.00 美元，并在 5 月 5 日星期一的研究报告中给予该股票 “跑输大盘” 的评级。Chardan Capital 在 7 月 29 日星期二的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价。最后，Oppenheimer 在 7 月 8 日星期二将 Praxis Precision Medicines 的目标价从 97.00 美元上调至 115.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了 “卖出” 评级，八位分析师则给予了 “买入” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 95.22 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
</div><h2>Praxis Precision Medicines Trading Down 6.5%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股价下跌 6.5%</h2>
</div><p>Shares of PRAX stock opened at $47.79 on Wednesday. The stock has a 50 day moving average of $47.56 and a two-hundred day moving average of $48.66. Praxis Precision Medicines has a 12 month low of $26.70 and a 12 month high of $91.83. The company has a market capitalization of $973.48 million, a P/E ratio of -3.89 and a beta of 2.62.</p>
<div class="lb-trans"><p>PRAX 股票在星期三开盘价为 47.79 美元。该股票的 50 日移动平均线为 47.56 美元，200 日移动平均线为 48.66 美元。Praxis Precision Medicines 的 12 个月低点为 26.70 美元，12 个月高点为 91.83 美元。该公司的市值为 9.7348 亿美元，市盈率为 -3.89，贝塔系数为 2.62。</p>
</div><h2>Hedge Funds Weigh In On Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>对 Praxis Precision Medicines 的对冲基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Praxis Precision Medicines by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,135 shares of the company's stock valued at $856,000 after purchasing an additional 258 shares during the last quarter. California State Teachers Retirement System raised its position in Praxis Precision Medicines by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 12,726 shares of the company's stock valued at $979,000 after purchasing an additional 275 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Praxis Precision Medicines by 88.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock valued at $26,000 after purchasing an additional 295 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Praxis Precision Medicines in the 4th quarter valued at $30,000. Finally, MetLife Investment Management LLC raised its position in Praxis Precision Medicines by 5.4% in the 4th quarter. MetLife Investment Management LLC now owns 10,675 shares of the company's stock valued at $822,000 after purchasing an additional 544 shares during the last quarter. Institutional investors own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了该公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第四季度将其在 Praxis Precision Medicines 的持仓增加了 2.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 11,135 股该公司的股票，价值 856,000 美元，此前在上个季度购买了 258 股。加利福尼亚州教师退休系统在第四季度将其在 Praxis Precision Medicines 的持仓增加了 2.2%。加利福尼亚州教师退休系统目前拥有 12,726 股该公司的股票，价值 979,000 美元，此前在上个季度购买了 275 股。Nisa Investment Advisors LLC 在第二季度将其在 Praxis Precision Medicines 的持仓增加了 88.3%。Nisa Investment Advisors LLC 目前拥有 629 股该公司的股票，价值 26,000 美元，此前在上个季度购买了 295 股。GF Fund Management CO. LTD. 在第四季度购买了 Praxis Precision Medicines 的新头寸，价值 30,000 美元。最后，MetLife Investment Management LLC 在第四季度将其在 Praxis Precision Medicines 的持仓增加了 5.4%。MetLife Investment Management LLC 目前拥有 10,675 股该公司的股票，价值 822,000 美元，此前在上个季度购买了 544 股。机构投资者持有该公司 67.84% 的股份。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗特发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>3 Sector ETFs Catching Fire After Earnings Beats</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Unusual Machines: A Speculation With Tailwinds to Lift Its Price</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Zebra Technologies: Riding the Automation Wave to Profits</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，超过 Praxis Precision Medicines</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>三只在财报超预期后火热的行业 ETF</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>不寻常的机器：一种有助于提升其价格的投机</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>Zebra Technologies：乘着自动化浪潮获利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 对 Praxis Precision Medicines 2029 财年收益的估计是多少？